Clinical Biochemical Test Data for Early-Stage Colon Adenocarcinoma (COAD) Patients

All cancer cases were histopathologically confirmed. Peripheral blood samples were collected at the time of outpatient diagnosis prior to treatment initiation, while samples from healthy controls were obtained during routine health examinations, with colorectal disease excluded by colonoscopy.The dataset contains comprehensive clinical and laboratory data derived from these participants, including serum biochemical indicators, tumor markers, immune cell profiling, and genomic mutation information.Serum biochemical data were obtained using an automated clinical chemistry analyzer under standardized laboratory conditions.

The dataset includes quantitative measurements of multiple proteins and enzymes related to lipid metabolism, liver function, oxidative stress, and inflammation (e.g., APOA1, APOB, APOE, ALB, TTR, CP, CYSC, NGAL, TF, GSR, ADA, and others). Tumor marker data include commonly used clinical indicators such as CEA, CA125, and CA199.Immune-related data were generated from flow cytometry analysis of peripheral blood samples. The dataset provides proportions of lymphocyte subsets, including T cells (CD3⁺, CD4⁺, CD8⁺), B cells, and NK cells, as well as expression levels of immune checkpoint molecules such as PD-1.Genomic data were obtained from formalin-fixed paraffin-embedded tumor tissues using targeted next-generation sequencing.